Scopolamine Hydrobromide
Loading...Scopolamine Hydrobromide Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Addiction does not occur, although vomiting, malaise, sweating and salivation have been reported in patients with parkinsonism upon sudden withdrawal of large doses of scopolamine. Scopolamine is one of the most important drugs of the belladonna group from the standpoint of poisoning; infants and young children are especially susceptible to the belladonna alkaloids. Scopolamine is usually stated more toxic than atropine. Idiosyncrasy is more common with scopolamine than with atropine and ordinary therapeutic doses sometimes cause alarming reactions.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Scopolamine Hydrobromide Injection, USP is indicated as a sedative and tranquilizing depressant to the central nervous system. In its peripheral actions, scopolamine differs from atropine in that it is a stronger blocking agent for the iris, ciliary body and salivary, bronchial and sweat glands but is weaker in its action on the heart (in which it is incapable of exerting actions in tolerated doses), the intestinal tract and bronchial musculature.
In addition to the usual uses for antimuscarinic drugs, scopolamine is employed for its central depressant actions as a sedative. Frequently it is given as a preanesthetic medicament for both its sedative-tranquilizing and antisecretory actions. It is an effective antiemetic. It is used in maniacal states, in delirium tremens and in obstetrics. As a mydriatic and cycloplegic, it has a somewhat shorter duration (3 to 7 days) and intraocular pressure is affected less markedly than with atropine.
History
There is currently no drug history available for this drug.
Other Information
Scopolamine Hydrobromide Injection, USP is a sterile solution of scopolamine hydrobromide (C17H21NO4 • HBr • 3H2O) in Water for Injection. The injection is preserved with methylparaben 0.18% and propylparaben 0.02%. Scopolamine Hydrobromide Injection is intended for intramuscular, intravenous and subcutaneous use. The pH (3.5-6.5) is adjusted with hydrobromic acid if necessary.
The structural formula is:
Sources
Scopolamine Hydrobromide Manufacturers
-
App Pharmaceuticals, Llc
![Scopolamine Hydrobromide Injection, Solution [App Pharmaceuticals, Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Scopolamine Hydrobromide | App Pharmaceuticals, Llc
AdultFor obstetric amnesia or preoperative sedation, 0.32 to 0.65 mg (320 to 650 mcg).
For sedation or tranquilization, 0.6 mg (600 mcg) 3 or 4 times a day.
Subcutaneous, as an antiemetic, 0.6 to 1 mg.
PediatricAge 6 mo. to 3 yr., 0.1 to 0.15 mg (100 to 150 mcg). Age 3 to 6 yr., 0.2 to 0.3 mg (200 to 300 mcg).
Subcutaneous, as antiemetic, 0.006 mg (6 mcg) per kg.
Dosage Equivalents
1 mg (1000 mcg)/mL
1 mg
(1000 mcg)
1 mL
0.8 mg
(800 mcg)
0.8 mL
0.6 mg
(600 mcg)
0.6 mL
0.5 mg
(500 mcg)
0.5 mL
0.4 mg
(400 mcg)
0.4 mL
0.3 mg
(300 mcg)
0.3 mL
0.2 mg
(200 mcg)
0.2 mL
0.1 mg
(100 mcg)
0.1 mL
0.4 mg (400 mcg)/mL
0.4 mg
(400 mcg)
1 mL
0.3 mg
(300 mcg)
0.75 mL
0.25 mg
(250 mcg)
0.63 mL
0.2 mg
(200 mcg)
0.50 mL
0.15 mg
(150 mcg)
0.38 mL
Belladonna alkaloids provide a therapeutic effect in about 1 or 2 hours with a duration of about 4 hours.
Geriatric and debilitated patients may respond to the usual doses with excitement, agitation, drowsiness or confusion; lower doses may be required in such patients.
Close supervision is recommended for infants, blondes, mongoloids and children with spastic paralysis or brain damage, since an increased responsiveness to belladonna alkaloids has been reported in these patients and dosage adjustments are often required.
Administration of belladonna alkaloids and barbiturates 30 to 60 minutes before meals is recommended to maximize absorption and, when issued for reducing stomach acid formation, to allow its effect to coincide better with antacid administration following the meal.
Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.
AdultFor obstetric amnesia or preoperative sedation, 0.32 to 0.65 mg (320 to 650 mcg).
For sedation or tranquilization, 0.6 mg (600 mcg) 3 or 4 times a day.
Subcutaneous, as an antiemetic, 0.6 to 1 mg.
PediatricAge 6 mo. to 3 yr., 0.1 to 0.15 mg (100 to 150 mcg). Age 3 to 6 yr., 0.2 to 0.3 mg (200 to 300 mcg).
Subcutaneous, as antiemetic, 0.006 mg (6 mcg) per kg.
Dosage Equivalents
1 mg (1000 mcg)/mL
1 mg
(1000 mcg)
1 mL
0.8 mg
(800 mcg)
0.8 mL
0.6 mg
(600 mcg)
0.6 mL
0.5 mg
(500 mcg)
0.5 mL
0.4 mg
(400 mcg)
0.4 mL
0.3 mg
(300 mcg)
0.3 mL
0.2 mg
(200 mcg)
0.2 mL
0.1 mg
(100 mcg)
0.1 mL
0.4 mg (400 mcg)/mL
0.4 mg
(400 mcg)
1 mL
0.3 mg
(300 mcg)
0.75 mL
0.25 mg
(250 mcg)
0.63 mL
0.2 mg
(200 mcg)
0.50 mL
0.15 mg
(150 mcg)
0.38 mL
Belladonna alkaloids provide a therapeutic effect in about 1 or 2 hours with a duration of about 4 hours.
Geriatric and debilitated patients may respond to the usual doses with excitement, agitation, drowsiness or confusion; lower doses may be required in such patients.
Close supervision is recommended for infants, blondes, mongoloids and children with spastic paralysis or brain damage, since an increased responsiveness to belladonna alkaloids has been reported in these patients and dosage adjustments are often required.
Administration of belladonna alkaloids and barbiturates 30 to 60 minutes before meals is recommended to maximize absorption and, when issued for reducing stomach acid formation, to allow its effect to coincide better with antacid administration following the meal.
Parenteral drug products should be inspected visually for particulate matter prior to administration, whenever solution and container permit.
Login To Your Free Account